Aims To evaluate the feasibility of using self-collected capillary blood samples for islet autoantibody testing to identify risk in relatives of people with Type 1 diabetes.
Introduction
Islet autoantibodies are indicators of b-cell autoimmunity and individuals with two or more islet autoantibodies have a >80% risk of developing Type 1 diabetes within 15 years [1] . A recent Type 1 diabetes staging classification system emphasized the importance of identifying islet autoimmunity in early pre-symptomatic stages, potentially allowing earlier intervention [2] . Prevention of progression to symptomatic disease requires large-scale screening to identify individuals at risk. Barriers to screening include geographical, cost and time constraints, as well as aversion to venepuncture, particularly in children. A simple test allowing self-collection of samples at home could overcome these limitations. Capillary sampling, having previously been validated against venous sampling for detection of islet autoantibodies [3] [4] [5] , offers a potential solution. We assessed the feasibility and acceptability of home self-collection of capillary samples for autoantibody screening among relatives of people with Type 1 diabetes.
Methods
This substudy of the TrialNet Pathway to Prevention [6] recruited relatives from 15 US centres between August and December 2015. Institutional review boards at each centre provided ethical approval. Families gave written informed consent. Some centres offered telephone consultations, with postal return of consent forms. Samples were tested for autoantibodies to glutamic acid decarboxylase (GAD), islet antigen-2 (IA-2), insulin and zinc transporter 8 (ZnT8), in accordance with the Pathway to Prevention study protocol, replacing venous sampling. Participants positive for ≥1 autoantibody or with unsuccessful capillary sampling were recalled for confirmatory venous testing. Age-banded recruitment ensured enrolment of adequate numbers of younger children.
Capillary sampling kits, containing BD Microtainer â contact-activated lancets (Becton Dickinson, Franklin Lakes, NJ, USA), Sarstedt Microvette â serum gel capillary tubes with clotting activator (Sarstedt Inc., Newton, NC, USA) with written and online instructions, were provided in person or by post. A minimum volume of 200 ll blood (up to 500 ll) was requested. Adults performed the procedure on children aged <12 years, whilst children aged 12-17 years collected samples themselves, or were aided by an adult. Acceptability of collection was assessed by questionnaire (Appendix S1). Samples were returned to clinical sites by overnight courier. Extracted serum was stored and sent to the central laboratory at À20°C. A radioimmunoassay was used to measure autoantibodies to GAD, IA-2, ZnT8 and insulin autoantibodies (IAA) in capillary serum samples in the TrialNet Core laboratory at the Barbara Davis Center for Childhood Diabetes, as previously described [6] . The same autoantibody thresholds were used for capillary serum as those used for venous serum in TrialNet studies.
The primary outcome of the study was successful sample collection, defined as sufficient volume and quality (e.g. without excessive haemolysis) to allow definitive autoantibody results, including confirmation of positive results by repeat assay. Secondary outcomes incorporated acceptability of sample collection and additional analyses to formulate an upper confidence bound of unsuccessful sampling.
Results are presented as median (range) unless otherwise stated. The upper confidence bound of unsuccessful sampling was calculated using the Clopper-Pearson interval. Chisquared tests were performed for categorical values. Nonparametric questionnaire scoring data were compared using Wilcoxon rank-sum and Kruskal-Wallis testing. Logistic regression was used to test for age effects in the risk of unsuccessful sample collection. P values <0.05 were considered significant. Statistical analysis was performed using SAS (SAS Inc.) and S-PLUS (TIBCO Software Inc.) software. Table 1 shows the demographic characteristics of the study participants. The median (range) interval between initial kit shipment and sample collection was 8 (0-104) days (n=158) and from sample collection to receipt at clinical centre was 2 (0-7) days (n=169).
Results
Rates of successful sample collection varied by autoantibody type (Table 1) , with the highest success for GAD, IA-2 and ZnT8 autoantibody screening. There was no significant haemolysis in any samples.
The upper 90% confidence bounds of unsuccessful capillary sample collection were 4.4% for GAD, IA-2 and ZnT8 autoantibody assays combined, and 19.3% for IAA. Sampling was unsuccessful for ≥1 autoantibody assay in 16.0% of participants aged ≤8 years, 17.5% of those aged 9-18 years and 14.5% of those aged >18 years. There was no difference in the rate of unsuccessful sampling among age groups or overall age effect (P=0.73).
Of five participants with positive autoantibodies, four had confirmatory venous testing. Three showed fully concordant venous and capillary results and one was concordant for GAD and IA-2 autoantibody positivity, but an IAA positive capillary sample was negative in the venous sample. Of 39 individuals with unsuccessful capillary sampling, six have provided venous samples to date. All capillary samples were insufficient for IAA only and in subsequent venous samples one individual was IAA positive and five were IAA negative.
Capillary collection was considered uncomfortable or painful by 43% of participants. Nonetheless, 82% preferred home capillary sampling over outpatient venepuncture. Preference for capillary sampling varied by age: 90% of those aged ≤8 years, 83% of those aged 9-18 years and 73% of those aged >18 years, with greater preference among younger children (P=0.01). The median (interquartile range) score for ease of testing, using a scale from 1 (easy) to 7 (difficult), was 3 (2-5), with no differences either among age
What's new?
• This is the first study to evaluate the use of capillary blood samples, collected at home by families themselves, for islet autoantibody testing.
• Capillary sampling was feasible and acceptable in all age groups including young children, with high rates of success in testing for glutamic acid decarboxylase, islet antigen 2 and zinc transporter 8 autoantibodies.
• The study highlights that insulin autoantibody assays were least likely to be successful, therefore, to avoid missing very young children at risk, second-line venous sampling may be required in this group.
• Screening of islet autoantibodies using this method is popular with families of people with Type 1 diabetes, particularly children. 
Discussion
Ease of sample collection has allowed the widespread adoption of capillary sampling in commercial self-testing for conditions such as hypercholesterolaemia and coeliac disease. Collection by clinicians has been used successfully for large-scale islet autoantibody testing in children [9] , including those as young as 2 years [10, 11] ; however, no published data exist on self-collection of capillary samples for islet autoantibody testing outside the clinical setting.
Capillary samples have shown high concordance with venous samples when compared for autoantibodies to GAD [3] [4] [5] , IA-2 [3-5] (or combined GAD/IA-2 assays) [3, 4] , ZnT8 [5] and IAA [4] . Using a panel of GAD, IA-2 and ZnT8 autoantibody assays, we have previously shown that 95.5% of individuals who were multiple autoantibody-positive in venous serum were concordant in capillary samples collected as dried blood spots and 98.6% of those who were autoantibody-negative were concordant in dried blood spot samples [5] .
Options for self-collection of capillary samples are direct collection of whole blood into tubes or dried blood spots on filter paper, with extraction of serum or eluates respectively. Both techniques offer sufficient stability to allow samples to be shipped at ambient temperature. Antibody levels are lower in dried blood eluates than in venous serum, particularly IAA, and weakly positive autoantibodies may be missed [3] , introducing a risk of overlooking individuals with a single positive autoantibody. Our previous study, which did not include IAA in the initial screen, showed 39% of relatives who were single autoantibody-positive in a venous sample were missed by dried blood spot sampling [5] . Assay optimization on dried blood spots has improved detection of IAA [12] , but collection of dried capillary samples, even by clinicians, resulted in variable quality, with 45% of samples insufficient to allow confirmation of positive results [5] .This limits adoption of dried blood spots in screening strategies, but collecting capillary whole blood into tubes could overcome these issues.
Of self-collected capillary samples, 16% were suboptimal for testing for the full panel of four autoantibodies because of insufficient volumes for IAA measurement, whereas only 3% were insufficient to measure GAD, IA-2 and ZnT8 autoantibodies. The confidence bounds for unsuccessful sample collection for GAD, IA-2 and ZnT8 autoantibody testing imply a 90% certainty that <4% would need retesting. Incorporating IAA potentially increases the rate of unsuccessful capillary sampling to 20%, largely because the more complex IAA radioimmunoassay requires fivefold greater volume than the other assays. Relatives were largely successful in collecting sufficient sample volumes to allow GAD, IA-2 and ZnT8 autoantibody testing. Previously, we showed that this panel identified multiple autoantibodypositive individuals with high sensitivity [5] , the potential risk would therefore be missing individuals who are positive for IAA alone. A fail-safe capillary screening strategy would incorporate recall for venous sampling to confirm positive results and for otherwise autoantibody-negative individuals with insufficient sample for IAA testing. Requesting a higher minimum volume could more consistently provide sufficient volumes for all assays. Seroconversion for IAA tends to occur at an early age [13] , which with current assays, may necessitate continued venous sampling to screen very young children. Strong preferences were demonstrated for home capillary sampling over venepuncture at a clinical centre, particularly among families of children aged <8 years. Extending procedures for obtaining informed consent remotely by telephone or online could further facilitate testing. Our sampling kits appear user-friendly, and clear written instructions were adequate for the majority of testers, with few referring to video instructions. No data were collected from families who declined capillary sampling or unreturned samples, potentially leading to bias. Importantly, participating families were already familiar with capillary glucose testing; therefore, the feasibility of capillary sampling in the general population requires further study.
Self-collected capillary blood samples are feasible and acceptable for autoantibody screening in individuals at risk of Type 1 diabetes, showing advantages over dried blood collection and preferred over outpatient venepuncture, particularly in children. With additional benefits of improving convenience and efficiency, home autoantibody testing through capillary sampling could aid Type 1 diabetes screening initiatives.
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